1. Scrip

Taking On Vyvgart In Myasthenia Gravis

 
• By Elizabeth Cairns

Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.  

Changes ahead

argenx N.V. might be justified in considering itself secure as market leader in the muscle weakening condition myasthenia gravis (MG), with its anti-neonatal Fc receptor (FcRn) antibody Vyvgart already a blockbuster in the condition.

Key Takeaways
  • Argenx is working to expand Vyvgart’s approved indications and settings, including in MG
  • But several other companies are working to the same end
  • And new entrants are trying to

But several products that are in the works appear to be flying under analysts’ radar, and with a flurry of late-stage clinical readouts

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.